vibostolimab + pembrolizumab + paclitaxel

This is a combination therapy consisting of **vibostolimab**, **pembrolizumab**, and **paclitaxel**. - **Vibostolimab** is a monoclonal antibody targeting TIGIT, developed for immune checkpoint inhibition in cancer therapy by enhancing anti-tumor immune activity. - **Pembrolizumab** (Keytruda) is a monoclonal antibody against PD-1, blocking the interaction with its ligands PD-L1 and PD-L2 to enhance T-cell responses against cancer cells. - **Paclitaxel** is a cytotoxic small molecule that stabilizes microtubules, inducing mitotic arrest and apoptosis in dividing tumor cells. This combination is being explored for anti-tumor activity, especially within the context of immunotherapy/chemotherapy regimens in oncology, including but not limited to non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). While extensive clinical trials and approvals exist for pembrolizumab + paclitaxel (and other chemotherapy agents), clinical data combining **vibostolimab** with both **pembrolizumab** and **paclitaxel** are investigational and not yet standard of care[1][2][5][6][7].